Price Chart

Profile

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
URL http://www.diamedica.com
Investor Relations URL https://www.diamedica.com/investors
HQ State/Province Minnesota
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 17, 2026 (est.)
Last Earnings Release Nov. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
URL http://www.diamedica.com
Investor Relations URL https://www.diamedica.com/investors
HQ State/Province Minnesota
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 17, 2026 (est.)
Last Earnings Release Nov. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A